Does 43647 require prior authorization?

No, 43647 does not require prior authorization (high confidence). Code is covered without prior authorization.

What is the Medicare reimbursement rate for 43647?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Verity

`43647`

HCPCS/CPT

Prior Authorization

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage; refer to the protocol titled Medical Records Documentation Used for Reviews. Preoperative evaluation that includes a detailed weight history along with dietary and physical activity patterns (required for adults under coverage criteria). Psychosocial-behavioral evaluation by an individual who is professionally recognized as part of a behavioral health discipline to provide screening and identification of risk factors or potential postoperative challenges that may contribute to a poor postoperative outcome (required for adults under coverage criteria) or participation in a Multidisciplinary surgical preparatory regimen (as an alternative per policy wording). For adolescents: evaluation at, or in consultation with, a Multidisciplinary center focused on the surgical treatment of severe childhood obesity (may include MBSAQIP-accredited adolescent centers or centers that demonstrate similar programmatic components). Evidence of OSA confirmation on polysomnography with an AHI or RDI of 63 30 when OSA is cited as a qualifying comorbidity. For obstruction: confirmation by imaging studies. For adjustable gastric band migration (slippage): records must demonstrate that manipulation or adjustment to correct band slippage has been attempted. For uncontrollable reflux related to sleeve gastrectomy: documentation of maximum nonpharmacological medical management failure; documentation of maximum pharmacological medical management failure (e.g., at least one month of double dose PPI, H2 blocker, and/or sucralfate); and endoscopy confirming severe esophagitis (grade C or D) despite maximum medical management. For planned two-stage procedures: documentation of initial BMI 63 50 kg/m2 prior to first stage, date of second stage (must be within 2 years), documentation of compliance with nutrition and exercise, and re-confirmation that individual meets medical necessity criteria at time of second stage procedure. For revisional procedures related to leaks, perforation, staple-line failure, mechanical device failure, etc.: operative, imaging, endoscopic, or pathology reports documenting the technical failure or major complication as the indication for revision. Comprehensive preoperative evaluation: "obesity-focused history, physical examination, and pertinent laboratory and diagnostic testing" (AACE/ASMBS guidance). Detailed weight history documenting prior attempts: "A detailed weight history should be documented, including a description of the onset and duration of obesity, the severity, and recent trends in weight... A brief summary of personal weight loss attempts, commercial plans, and physician-supervised programs should be reviewed and documented, along with the greatest duration of weight loss and maintenance." (AACE/ASMBS guidance). Evidence of failure of conservative measures where relevant: many device and guideline recommendations require that patients have "failed conservative weight reduction strategies" (e.g., ORBERA indication: failed supervised diet, exercise, and behavior modification). Psychosocial / behavioral health assessment: "all bariatric surgery candidates be evaluated by a licensed mental health care provider experienced in the treatment of severely obese patients" and preoperative psychosocial evaluation per ASMBS (Sogg et al., 2016). Multidisciplinary team involvement and plan for long-term follow-up: multiple society recommendations require multidisciplinary care (medical, nutritional, psychological, exercise counseling) and an established mechanism for long-term follow-up care (ASGE, ASMBS, NICE, ADA). Preoperative nutritional assessment and recommended perioperative nutritional monitoring: ASMBS recommends preoperative screening for vitamin deficiencies and that long-term monitoring of micronutrient and nutritional status be provided after surgery (Parrott et al., 2017; ADA 2024 statement). Informed consent describing device- and procedure-specific risks, tolerance issues, potential for early device removal, and potential for weight regain: ASMBS addendum on intragastric balloons and other sections emphasize informed consent and counseling about adverse events and expected postoperative course. For procedures performed under research or limited-use guidance (e.g., DJBL / EndoBarrier per NICE): documentation of research governance, patient selection criteria, complications, reasons for early removal, medication use while device in place and after removal, and diabetes control after removal are required to meet research-use recommendations. For FDA-labeled device indications (e.g., TPS, ORBERA): documentation that device use conforms to labeled inclusion criteria (age, BMI range, presence of comorbidities as applicable) and that device is used "in conjunction with a diet and behavior modification program." Perioperative and postoperative visit and monitoring schedules described in RCTs/devices (examples): e.g., ESG MERIT trial: 12 follow-up visits in first year (weeks 1 and 4, then every 4 weeks until 52 weeks). Documentation of follow-up attendance and outcomes may be required to support continued device use or coverage.

Key Coverage Criteria

The following bariatric surgical procedures are proven and medically necessary for treating obesity: Biliopancreatic diversion/biliopancreatic diversion with duodenal switch; Gastric bypass (includes robotic-assisted gastric bypass); Adjustable gastric banding (using open or laparoscopic approaches) for individuals 63; Sleeve gastrectomy (vertical sleeve gastrectomy). [...]
"MBS is recommended for individuals with a BMI ≥ 35 kg/m², regardless of presence, absence, or severity of comorbidities" (ASMBS/IFSO update).
"MBS should be considered for individuals with metabolic disease and BMI of 30-34.9 kg/m²" (ASMBS/IFSO update).
ADA Standards: "metabolic surgery should be considered as a weight and glycemic management approach for individuals with diabetes with a BMI ≥ 30.0 kg/m² (or ≥ 27.5 kg/m² in Asian American individuals) who are otherwise good candidates for surgery." AACE/ACE/AACE-ASMBS recommendations: "Patients with a BMI ≥ 40 kg/m² without coexisting medical problems ... eligible; Patients with a BMI ≥ 35 kg/m² and one or more severe obesity-related complications remediable by weight loss ... [...]
Per oral endoscopic myotomy (POEM) procedure is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm. AGA: Stepwise approach for individuals presenting with GERD symptoms; when symptoms persist despite lifestyle changes and optimal medication use, management strategies should be tailored based on factors such as the integrity of the anti-reflux barrier, presence of visceral hypersensitivity and hypervigilance, confirmation of PPI-refractory GERD, sym [...]
Stretta System: approved for radiofrequency thermal ablation treatment of GERD.

12 Active Policies

AMBETTER-CP.MP.37 — Bariatric Surgery

AMBETTER-CP.MP.40 — Gastric Electrical Stimulation

UHC-POL-bariatric-surgery — Bariatric Surgery

UHC-POL-minimally-invasive-procedures-gerd-achalasia — Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

UMR-POL-UMR-bariatric-surgery — Bariatric Surgery

Have a follow-up question?

Ask Verity about documentation requirements, denial risks, or coverage in your state.

No explicit documentation requirements are specified in the provided policy text chunk. Note: Clinical evidence summaries and device FDA indications cited in the policy reference use of diagnostic tests in trials (e.g., esophageal pH testing, manometry, pathologic esophageal acid exposure, hiatal hernia size) but the policy text does not list these as formal documentation requirements for coverage in this excerpt. Documentation of 'careful discussion with the patient regarding potential adverse effects, benefits, and other available therapeutic options' when considering endoscopic antireflux therapy (ASGE recommendation). For TIF/EsophyX: documentation that patient has symptomatic chronic GERD, 'requires and responds to pharmacologic therapy', has not obtained satisfactory relief from a standard dose of PPI therapy OR wishes to avoid lifetime drug therapy, and documentation of hiatal hernia size ≤ 2 cm where applicable (ASGS / EsophyX device labeling). For Stretta: documentation that patient is >18 years old; has heartburn/regurgitation symptoms for ≥6 months; has been partially or completely responsive to anti-secretory pharmacologic therapy; and has declined laparoscopic fundoplication (SAGES criteria). For LINX and other implantable devices: documentation of clinician/surgeon training and experience in laparoscopic foregut surgery and management of GERD; documentation of patient selection criteria and informed consent regarding device-specific risks (erosion, dysphagia, need for dilation/explanation). For POEM or other achalasia interventions: documentation of achalasia subtype, prior treatment(s) (if any), rationale for chosen therapy (POEM vs Heller vs pneumatic dilation), and consideration of local expertise and patient preference (SAGES / ASGE guidance). For EndoFLIP: documentation showing EndoFLIP used as an adjunct to other diagnostic methods as part of a comprehensive evaluation of patients with symptoms consistent with gastrointestinal motility disorders (per device labeling). Documentation of trials of lifestyle modification and 'optimal medication use' (including PPI therapy) and confirmation of PPI-refractory GERD when relevant (AGA clinical practice update guidance). Administrative/documentation requirement: check member-specific benefit plan and any applicable federal/state mandates; in absence of Medicare NCD/LCD, MAO may apply its own coverage determinations — documentation should reference applicable plan/NCD/LCD if used to support coverage.

43647